Pharmacophore Modeling of Nilotinib as an Inhibitor of ATP-Binding Cassette Drug Transporters and BCR-ABL Kinase Using a Three-Dimensional Quantitative Structure–Activity Relationship Approach

[Image: see text] Nilotinib (Tasigna) is a tyrosine kinase inhibitor approved by the FDA to treat chronic phase chronic myeloid leukemia patients. It is also a transport substrate of the ATP-binding cassette (ABC) drug efflux transporters ABCB1 (P-glycoprotein, P-gp) and ABCG2 (BCRP), which may have...

Descripción completa

Detalles Bibliográficos
Autores principales: Shukla, Suneet, Kouanda, Abdul, Silverton, Latoya, Talele, Tanaji T., Ambudkar, Suresh V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2014
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4086741/
https://www.ncbi.nlm.nih.gov/pubmed/24865254
http://dx.doi.org/10.1021/mp400762h

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4086741/
https://www.ncbi.nlm.nih.gov/pubmed/24865254
http://dx.doi.org/10.1021/mp400762h

Ejemplares similares